Nav: Home

Enhanced anticancer compound may allow precise activation and tracking of treatment

May 15, 2019

PHILADELPHIA -- (May 15, 2019) -- Researchers at The Wistar Institute and the University of South Florida have advanced a novel compound that specifically targets the endoplasmic reticulum (ER) stress response that is frequently hyperactivated in cancer and promotes survival of cancer cells during stressful conditions. The new compound has unique chemical properties that allow for precise activation and can be used for tracking its activity in vivo thanks to the emission of fluorescence. Research was published online in the Journal of Medicinal Chemistry.

The ER is a cellular structure that oversees protein folding and assembly, and it activates stress response mechanisms in response to the accumulation of misfolded proteins or other stressful conditions, including low oxygen.

"Certain cancers rely on the protective role of the ER stress response to sustain their growth in stressful environmental conditions," said Chih-Chi Andrew Hu, Ph.D., associate professor in Wistar's Immunology, Microenvironment & Metastasis Program, and co-lead author on the study with Juan R. Del Valle, Ph.D., from the University of South Florida. "We and other groups showed that genetically and pharmacologically targeting the ER is a very effective way to attack various tumors."

The Hu lab has been actively advancing a research program for development of compounds to block vital functions of the ER stress response, specifically inhibitors of the IRE1 protein that senses the ER stress and responds by activating a cascade of cellular events. In addition to inducing tumor cell apoptosis, these compounds activate antitumor T-cell function and inhibit tumor-associated immunosuppressive cells in vivo in mouse models, resulting in tumor shrinkage.

"This class of inhibitors has shown therapeutic promise in several cancer types, including chronic lymphocytic leukemia and Burkitt lymphoma," said Hu. "Therefore, we are very interested in advancing them to the clinic."

In this study, through a series of chemical modifications, Hu and collaborators created a molecule called PC-D-F07 that is pharmacologically inactive and requires UV irradiation to be "turned on" and converted into the active D-F07, which is a very potent inhibitor of IRE-1 function.

The novel prodrug strategy enhances the efficacy of IRE-1 inhibitors and allows fine control of their activity at a precise time and location by UV irradiation. Importantly, once active, D-F07 emits fluorescence that can be tracked in cells and potentially in vivo, providing a real-time therapy readout. This new strategy for stimulus-mediated release of pharmacological activity provides a promising platform to target the ER stress response for anticancer therapy and for developing other potent inhibitors.
-end-
Co-authors: First author Andong Shao, Chih-Hang Anthony Tang, Qin Xu and Claire Phoumyvong from Wistar; Chang Won Kang, Christopher Cain and Juan R. Del Valle from University of South Florida.

Work supported by: National Institutes of Health (NIH) grants R01CA163910, R21CA199553, and R01CA190860.

Publication information: Structural tailoring of a novel fluorescent IRE-1 RNase inhibitor to precisely control its activity, Journal of Medicinal Chemistry (2019). Advance online publication.

The Wistar Institute is an international leader in biomedical research with special expertise in cancer, immunology, infectious disease research, and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. wistar.org.

The Wistar Institute

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Clint Smith
The killing of George Floyd by a police officer has sparked massive protests nationwide. This hour, writer and scholar Clint Smith reflects on this moment, through conversation, letters, and poetry.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Nina
Producer Tracie Hunte stumbled into a duet between Nina Simone and the sounds of protest outside her apartment. Then she discovered a performance by Nina on April 7, 1968 - three days after the assassination of Dr. Martin Luther King Jr. Tracie talks about what Nina's music, born during another time when our country was facing questions that seemed to have no answer, meant then and why it still resonates today.  Listen to Nina's brother, Samuel Waymon, talk about that April 7th concert here.